• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY: TAK )

    13.10 +0.09 (+0.69%)
    Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Takeda Pharmaceutical Company Limited American Depositary Shares (each

    < Previous 1 2 3 4 5 6 7 Next >
    HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
    — US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — 
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
    Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment. 
    Via MarketBeat
    Topics Economy
    Exposures Interest Rates
    Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    New Study Reveals How Classical Music Could Revolutionize Depression Care
    In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
    Via PressReach
    Exposures Product Safety
    Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Announces New Assignments of Directors
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.